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Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) 
and JAK2, significantly reduces splenomegaly and disease‐related symptoms in pa-
tients with myelofibrosis (MF). However, no clear survival benefit has been demon-
strated, which may in part reflect suboptimal drug exposure related to lower dosages 
needed to minimize hematological toxicity, specifically cytopenias. Furthermore, the 
optimal management of specific conditions such as leukocytosis or thrombocytosis 
in patients under ruxolitinib therapy is still undefined. In these cases, combining 
ruxolitinib with a cytoreductive agent like hydroxyurea might improve hematologi-
cal response. This observational multi‐center study enrolled 20 adult patients with 
intermediate‐ or high‐risk primary MF, post‐ polycythemia vera MF, or postessential 
thrombocythemia MF with hyperproliferative manifestations of the disease and 
WBC and/or platelet counts not controlled by ruxolitinib therapy. The patients re-
ceived treatment with a combination of ruxolitinib and hydroxyurea. A clinical re-
sponse of any type was obtained in 8 patients (40%) during ruxolitinib monotherapy 
and in 17 patients (85%) during ruxolitinib‐hydroxyurea combination (P = 0.003). 
After a median duration of 12.4 months of combination therapy, 16/20 patients had a 
hematological response; 14/17 patients who had started combination therapy to con-
trol WBC count and 2/3 who started in order to reduce platelets count. The number 
of patients requiring ruxolitinib dosage reduction or discontinuations was lower dur-
ing combination therapy and, at the end of follow‐up the median ruxolitinib dose was 
increased in 50% of patients. In conclusion, the combination of hydroxyurea with 
ruxolitinib yielded a high clinical response rate and increased ruxolitinib exposure in 
patients with hyperproliferative forms of MF.
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1 |  INTRODUCTION
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm 
(MPN) characterized by bone marrow fibrosis and extra-
medullary hematopoiesis, primarily manifested as spleno-
megaly.1-3 The clinical features and the evolution of MF are 
highly variable and include progressive anemia, leukopenia 
or leukocytosis, thrombocytopenia or thrombocytosis, and 
symptomatic splenomegaly.4
In the majority of patients with MF, symptoms feature and 
burden together with the IPSS score5,6 are the main deter-
minants of treatment choice. Therapeutic options included 
best supportive care/transfusion support, cytoreduction with 
hydroxyurea or interferon, use of erythropoietin stimulating 
agents, immunomodulatory drugs such as thalidomide and 
lenalidomide, danazol, radiotherapy, and splenectomy.5,6 
Among these, hydroxyurea has been shown to have a signif-
icant impact on the reduction in spleen and liver size, con-
stitutional symptoms, pruritus, and bone pain, and to control 
leukocytosis and thrombocytosis, with a reported overall 
response rate of 40% and a median duration of response of 
13.2 months.7
However, after the discovery of dysregulation of the Janus 
kinase (JAK) pathway, most commonly JAK2 V617F muta-
tion, in over half of MF patients,8,9 targeted therapies with 
JAK inhibitors have demonstrated improvements in spleno-
megaly, burden of symptoms, and a potential gain in overall 
survival.10,11
Two pivotal Phase III studies, COMFORT I and II, 
demonstrated that the potent and selective inhibitor of JAK1 
and JAK2, ruxolitinib, had great efficacy in reducing sple-
nomegaly and disease‐related symptoms, however, without 
a clear demonstration of benefits in terms of survival.10,11 
Afterwards, longer term follow‐up and pooled analysis of 
COMFORT I and II supported a survival benefit for MF pa-
tients who received treatment with ruxolitinib.12,13 It has been 
suggested that the lack of survival benefit observed in the 
pivotal studies may reflect the necessity for dosage modu-
lations, mostly due to hematological toxicity, but also to re-
duced control of disease, resulting in a reduced overall drug 
exposure.14 Noteworthy, drug discontinuations were associ-
ated with cytopenia, loss of spleen response and disease pro-
gression expressed by leukocytosis.
For these reasons, a combination of ruxolitinib and a cy-
toreductive agent such as hydroxyurea may be hypothesized 
to improve hematological response in the “hyperprolifer-
ative” forms of the disease, characterized by constitutional 
symptoms, marked splenomegaly, leukocytosis, and/or 
thrombocytosis. However, to date, there are only anecdotal 
reports about the value and efficacy of the addition of hy-
droxyurea to ruxolitinib treatment.15-17
Although the primary target of ruxolitinib therapy in MF 
is to control spleen‐ and disease‐related symptoms, the recent 
consensus report of the International Working Group (IWG) 
and the European LeukemiaNet (ELN) also includes WBC 
and platelet count control to below the upper limit of normal 
among their revised response criteria for treatment response 
for MF.18,19
To this end, in this study, patients affected by MF and with 
leukocytosis and/or thrombocytosis uncontrolled while on 
ruxolitinib monotherapy were moved to combination treat-
ment with ruxolitinib plus hydroxyurea.
2 |  METHODS
This retrospective multicenter case series, collected on a 
survey basis, was conducted from April 2012 to April 2017, 
and 20 adult patients (≥18 years of age) with a confirmed 
diagnosis of primary MF (PMF), post‐polycythemia vera 
(PPV‐MF), or post‐essential thrombocythemia (PET‐MF) 
with hyperproliferative manifestations of the disease were 
enrolled. Patients who were scheduled to receive hydroxyu-
rea in combination with ruxolitinib at the time when WBC 
and/or platelet count were in the upper to normal range 
(WBC > 10.0 × 109/L and platelets > 400 × 109/L),18,19 
while on ruxolitinib monotherapy, regardless of symptom 
improvements and spleen response obtained while on treat-
ment with ruxolitinib, were included in this analysis. Patients 
at the time of starting ruxolitinib had intermediate or high‐
risk disease according to the IWG for MF.20
2.1 | Treatment schedule
All patients evaluated had received ruxolitinib orally twice 
daily continuously at a starting dose based on baseline plate-
let count: 5 mg twice daily bis in die (BID), platelets 50 to 
<100 × 109/L; 15 mg BID, 100‐200 × 109/L; or 20 mg BID, 
>200 × 109/L according to the dosage schedule established 
by the drug data sheet.21 If platelet and neutrophil count were 
not controlled by therapy and/or treatment efficacy was in-
sufficient, ruxolitinib doses were modified by 5 mg BID in-
crements (up to 25 mg BID).21
The starting dose of hydroxyurea during combination 
therapy was based on clinician choice and modulated on the 
basis of WBC and platelet count and on the maximum rux-
olitinib dose tolerated by each individual patient. The initial 
doses for combination therapy were classified as follow: low 
doses, that is, low ruxolitinib (<10 mg BID)/low hydroxy-
urea (<1000 mg/daily); high doses, ie ruxolitinib (≥10 mg 
BID)/high hydroxyurea (≥1000 mg/daily) and intermediate 
doses, that is, low ruxolitinib/high hydroxyurea or high rux-
olitinib/low hydroxyurea. Doses of both hydroxyurea and 
ruxolitinib were modulated according to efficacy on disease 
symptoms and adverse events. The combined treatment was 
continued unless significant toxicity was observed or WBC 
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and/or platelet control was obtained. Discontinuation of rux-
olitinib was defined as a period of time in which patients 
needed treatment interruption due to side effects. Treatment 
could be resumed after recovering. Side effects were assessed 
and graded according to National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.03.22
2.2 | Response assessment
Patient responses were defined according to ELN criteria.18,19 
Response were stratified on the basis of initial combination 
doses.
Symptoms were evaluated by using MPN Symptom 
Assessment Form questionnaires,23 and a reduction in ≥50% 
of symptoms was considered as a response to treatment. 
Spleen size was assessed by physical examination. A base-
line splenomegaly palpable at 5‐10 cm from the left costal 
margin (LCM) that became nonpalpable or a baseline sple-
nomegaly palpable >10 cm from the LCM that decreased 
by ≥50% was considered as a response to treatment.18,19 In 
terms of hematological parameters, a WBC count of between 
4 and 10 × 109/L and a platelet count of between 100 and 
400 × 109/L were considered to be a complete response.18,19
3 |  RESULTS
Twenty patients with PMF, PPV, PET, treated at 6 hematol-
ogy divisions, were included and retrospectively analyzed. 
All patients had received ruxolitinib as monotherapy for a 
median duration of 15.9 months (range 1.6‐181 months) from 
MF diagnosis. The baseline characteristics of the patients 
when ruxolitinib was started are summarized in Table 1. 
Nineteen patients had received a median of one prior ther-
apy (range 1‐4) for MF. Nineteen patients (95%) had been 
treated with hydroxyurea as a single agent, 5 patients (25%) 
had received corticosteroid treatment, 2 patients (10%) had 
received pegylated interferon alpha, and 1 patient (5%) had 
received danazol. The starting dose of ruxolitinib as mono-
therapy was 20 mg BID for 8 patients (40%), 15 mg BID for 
7 patients (35%), 10 mg BID for one patient (5%), 5 mg BID 
for 4 patients (20%).
At the starting time of the study, 17 patients (85%) 
started hydroxyurea treatment due to lack of WBC control, 
whereas the remaining three patients (15%) started for the 
lack of platelet control, two of these had platelet counts of 
2000 × 109/L (Table 2). Among patients who started com-
bination therapy due to leukocytosis, four patients had plate-
let counts below 100 × 109/L. On the other hand, among the 
three patients who started combination therapy because of 
unsatisfactory platelet control, all patients showed a WBC 
count below 10 × 109/L. The addition of hydroxyurea was 
performed after a median time of ruxolitinib monotherapy 
of 6.5 months (range 1‐49.6 months). The starting doses of 
the two drugs at the beginning of the combination therapy 
were as follow: hydroxyurea 500 mg daily plus ruxolitinib 
5 mg BID for 6 patients (30%), hydroxyurea 1000 mg daily 
plus ruxolitinib 5 mg BID for 2 patients (10%), hydroxy-
urea 500 mg daily plus ruxolitinib 10 mg BID for 3 patients 
(15%), hydroxyurea 1000 mg daily plus ruxolitinib 10 mg 
BID for 1 patient (5%), hydroxyurea 1000 mg daily plus 
ruxolitinib 15 mg BID for 4 patients (20%), hydroxyurea 
1000 mg daily plus ruxolitinib 20 mg BID for 2 patients 
(10%) and hydroxyurea >1000 mg daily plus ruxolitinib 
20 mg BID for the remaining 2 patients (10%). Overall, six 
T A B L E  1  Baseline clinical characteristics of the patients at the 






Median (range) 64 (36‐82)
Myelofibrosis subtype
Primary myelofibrosis 7 (35)
Post‐polycythemia vera myelofibrosis 6 (30)






Median (range) 10.9 (7.5‐15.3)
Pts with anemiaa (%) 13 (65)
Platelet count—×109/L
Median (range) 212 (63‐800)
Pts with thrombocytosisb (%) 5 (25)
WBC count—×109/L
Median (range) 18.6 (4.9‐58.4)




Median (range) 18 (8.9‐24)




aAnemia not attributed to a comorbid condition. 
bLeukocytosis > 11 × 109/L. 
cThrombocytosis ≥ 450 × 109/L. 
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patients received low initial doses, five patients received 
intermediate doses and the remaining 9 patients received 
high combination doses.
The median time of the combination therapy was 
14.5 months (range 2‐195).
While on ruxolitinib monotherapy, 10 patients (50%) 
needed a dose reduction due to hematological toxicity and 
three patients temporarily discontinued ruxolitinib due to 
severe thrombocytopenia (15%), as shown in Table 3 and in 
Figure 1.
The combined ruxolitinib/hydroxyurea therapy was very 
well tolerated, and the hematological toxicities mostly oc-
curred in the first 8‐12 weeks of treatment, and were gen-
erally manageable with dose reductions and/or supportive 
treatment. In eight patients the ruxolitinib daily doses in-
creased (mean increase = 5.1 mg BID), in 9 the dose was 
unmodified despite the addition of hydroxyurea, and only 
in three cases the ruxolitinib dose had to be reduced (mean 
reduction = 3.4 mg BID). Overall, the mean daily dose of 
ruxolitinib administered to the whole cohort of patients in-
creased by 1.8 mg BID (P = 0.013), and only one patient had 
to discontinue ruxolitinib, due to severe thrombocytopenia 
(Figure 1). The dose of hydroxyurea was down‐modulated in 
eight patients (40%) according to the individual hematolog-
ical compliance to the treatment. Nonhematological adverse 
events were not observed.
After a median of 11.1 months (range 2‐35 months) of 
ruxolitinib monotherapy, 6 patients obtained a clinical im-
provement in MF‐associated symptomatic burden, consisting 
of improvement of symptoms and spleen improvement in 
5 of them and improvement of symptoms in the remaining 
patient. After a median 12.4 months (range 4‐44 months) 
of combination therapy, of the 17 patients who started the 
combination therapy to control WBC count, 14 (82.3%) ob-
tained a WBC response, whereas, among the three patients 
who started hydroxyurea in association with ruxolitinib in 
order to reduce platelets count, 2 (66.6%) achieved a platelet 
response. Data relating to response according to dose of the 
combination therapy are reported in Table 4.
In addition, 12 patients of the whole study cohort had 
clinical improvement in MF‐associated symptomatic burden, 
with 9 of them showing spleen and symptoms response and 
the remaining three only spleen responses (Table 4). Of note, 
all eight patients in whom ruxolitinib dose was increased had 
at least one type of drug‐related clinical response.
4 |  DISCUSSION
We describe a retrospective multi‐center case series carried 
out to investigate the role of the combination of hydroxyurea 
T A B L E  2  Patient characteristics at the start of combination 
therapy
Variable
Reason for adding hydroxyurea
Leukocytosis 
control (n = 17)
Thrombocytosis 
control (n = 3)
Time of ruxolitinib monotherapy
Median (range) 18 (1‐49.6) 3.74 (3‐13)
Hemoglobin—g/dL
Median (range) 11 (6.7‐13) 9.2 (8.5‐10.2)
Platelet count—×109/L
Median (range) 214.5 (27‐405) 2000 (558‐2000)
White blood cell count—×109/L
Median (range) 21.4 (16.1‐69.9) 7.0 (2.3‐8.0)
Splenomegaly
Present 17 (100) 3 (100)
Hydroxyurea starting dose, g
Median (range) 0.5 (0.5‐1.0) 2.0 (0.5‐3.0)
Time of combination therapy
Median (range) 9.5 (4‐44) 6.0 (4‐18)
T A B L E  3  Adverse events observed in patients during the ruxolitinib monotherapy and the combination treatment
 Ruxolitinib monotherapy (n = 20) Ruxolitinib plus Hydroxyurea (n = 20)
Hematological toxicitya All grades Grade 3 or 4 All grades Grade 3 or 4
Thrombocytopenia 6 (30) 3 (15) 8 (40) 2 (10)
Anemia 11 (55) 2 (10) 7 (35) 2 (10)
Neutropenia 2 (10) — 1 (5) —
Ruxolitinib discontinuation 3 (15) 1 (5)
Ruxolitinib dose reduction 10 (50) 2 (10)
Hydroxyurea discontinuation — 5 (25)
Hydroxyurea dose reduction — 8 (40)
Unless otherwise indicated, data are number of patients, with percentage in parentheses.
aHematologic abnormalities are based on laboratory values. The data shown are for the events of the worst grade during the study, regardless of whether this grade was 
a change from the baseline grade. 
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with ruxolitinib in adult patients with hyperproliferative 
forms of MF.
Ruxolitinib, the first JAK inhibitor approved for the treat-
ment of MF, is generally well tolerated, with thrombocyto-
penia as the dose‐limiting toxicity; evidence from clinical 
trials support the efficacy of ruxolitinib for hyperproliferative 
manifestations of MF.10-12,21,24-27 Reduction in spleen size 
and control of symptoms are usually rapid and durable, but 
also drug‐ and dose‐dependent, given that discontinuing or 
reducing the dose of ruxolitinib is followed by rapid increase 
in spleen size and reappearance of symptoms. Although hy-
droxyurea is widely used to attenuate hyperproliferative man-
ifestations related to MF, there are few well‐designed studies 
evaluating hydroxyurea benefits in patients with MF.7,28,29 
In a group of 40 patients with PMF, Martinez‐Trillos et al. 
showed significant response rates, with reductions in consti-
tutional symptoms (55%), symptomatic splenomegaly (45%), 
thrombocytosis (40%), and leukocytosis (28%). Accentuation 
of anemia was the most common adverse event and was ob-
served in almost half of the patients.7
To the best of our knowledge, this is the first retrospec-
tive case series to determine the feasibility and efficacy of 
combining ruxolitinib with hydroxyurea in a particular set-
ting of MF patients affected by hyperproliferative disease. 
In this case series, patients in which ruxolitinib monother-
apy was unable to reduce WBC and platelet within normal 
ranges (WBC ≤ 10.0 × 109/L or platelet ≤ 400 × 109/L)18,19 
received the combination in order to overcome hematological 
resistance and to better control disease‐related symptoms and 
splenomegaly.
Overall, in our study, ruxolitinib plus hydroxyurea in-
duced a hematological response in all but four patients, 
independently of initial combination doses. In addition, 
this combination therapy induces a higher rate of either 
spleen and symptoms responses than those observed after 
the ruxolitinib monotherapy (spleen response was obtained 
in 5 patients receiving ruxolitinib monotherapy vs 8 re-
ceiving the combination; symptoms response was reached 
in 6 vs 12 patients treated with ruxolitinib monotherapy 
and in combination with hydroxyurea, respectively). This 
slight difference is not statistically significant and we can-
not state with certainty that the improvement in the spleen 
response depends on the combination or on the doses of 
each drug (which, in the case of ruxolitinib, increases with 
F I G U R E  1  Dose profiles of ruxolitinib in 20 patients treated with ruxolitinib monotherapy and ruxolitinib in combination with hydroxyurea
   | 2807PUGLIESE Et aL.
the combination therapy). Indeed, the rate of spleen and 
symptoms response was lower for the patients on low doses 
compared with those on intermediate and high doses. Even 
if this difference was not statistical significant, it could 
suggest that spleen and symptoms responses are also dose 
dependent during combination therapy. On the other hand, 
it cannot be excluded that a late response would, in any 
case, have been observed with monotherapy.
The addition of hydroxyurea to ruxolitinib did not result 
in lower compliance to the latter drug. Instead, we were able 
to increase the ruxolitinib dose in 8 patients, and only three 
patients had to reduce the dose of this drug. Only 2 patients 
(10%) experienced severe thrombocytopenia, although only 
1 patient needed temporary drug discontinuation. For the 
remaining patients, platelet counts initially decreased and 
subsequently stabilized at a new steady state. On the other 
hand, it is plausible that the increase in overall treatment in-
tensity may be the main determinant for the better outcome 
of the therapy (all patients with ruxolitinib dose increase 
had experienced improvement). Indeed, our results indicate 
that combination of ruxolitinib and hydroxyurea results in 
enhanced efficacy of the treatment not only regarding he-
matological responses, observed in 16 out 20 patients, but 
also in terms of clinical responses, that is, splenomegaly and 
control of symptoms, observed in 12 out the 20 patients. In 
this regard, it should be underlined that both leukocytosis 
and thrombocytosis are associated with an enhanced risk of 
cardiovascular events.30-32 In addition, the combination of 
hydroxyurea with ruxolitinib, besides giving better clinical 
control of the disease, allowed the dose of the latter drug to 
be increased and the duration of its administration to be pro-
longed. Long‐term follow‐up from COMFORT‐II indicates 
that prolonged exposure to ruxolitinib therapy has a positive 
impact on the probability of survival of patients. Indeed, me-
dian overall survival was not reached in the ruxolitinib arm, 
vs 4.1 years in the best available therapy (BAT) arm, with a 
33% reduction in risk of death with ruxolitinib vs BAT by 
intent‐to‐treat analysis.12
Our study has several limitations which must be pointed 
out. Firstly, it is a multi‐center retrospective study with a 
small number of patients, which limits statistical power. 
Hence, our findings need to be validated in a large pro-
spective trial. In particular, the stratification of response on 
the basis of combination doses does not allow a statistical 
analysis. Secondly, although all centers used the same cri-
terion regarding platelet and leukocyte control to start the 
combination therapy, the starting dose of hydroxyurea and 
the dose used during the combination period were based 
on clinician choice (whereas the ruxolitinib dosage was 
modulated according to the dosage schedule established by 
the drug data sheet19). Therefore, a prespecified protocol 
was not used for the hydroxyurea dose. Indeed, to the best 
of our knowledge, there are no guidelines on the initial 
dose of hydroxyurea in patients with MF. Thirdly, WBC 
and platelet count control below the upper limit of normal 
as response criteria for MF are not recommended for use 
in the clinical practice, due to the lack of well documented 
benefit to outcome. Even if we can define with certainty 
that leukocytosis represents an unfavorable prognostic fac-
tor in patients with MF and therefore controlling it could 
be expected to improve the outcome of the patients, there 
is no unequivocal interpretation of the prognostic value of 
thrombocytosis or of any additional risk it imposes.20,30-34 
On the other hand, 2 of the 3 patients who started combi-
nation therapy for failure to control the platelet count had 
platelet counts above > 1500 × 109/L; this value unques-
tionably represents a condition of hemorrhagic risk that re-
quires a cytoreductive therapy for control of platelets.30,35
In conclusion, the combination of ruxolitinib with hydroxy-
urea is an effective and relatively well‐tolerated therapy for the 
hyperproliferative manifestations of MF, independently of com-
bination dose. Accentuation of the thrombocytopenia, usually 




apy (n = 20)
Ruxolitinib plus hydroxyurea
All patients 
(n = 20) Low doses (n = 6)
Intermediate 
doses (n = 5)
High doses 
(n = 9)
Duration of treatment, months, 
median (range)
11.1 (2‐35) 12.4 (4‐44) 10.5 (4‐19) 9 (5‐19) 10 (4‐44)
Clinical response of any type 8/20 (40.0) 17/20 (85.0) 5 (83.3) 4 (80.0) 8 (88.9)
Symptoms response 6/20 (30.0) 12/20 (60.0) 2 (33.3) 4 (80.0) 6 (66.7)
Spleen response 5/20 (25.0) 9/20 (45.0) 1 (16.7) 3 (60.0) 5 (44.4)
White blood cell response — 14/17 (82.3) 4/6 (66.7) 4/5 (80.0) 6/6 (100.0)
Platelet response — 2/3 (66.7) — — 2/3 (66.7)
Unless otherwise indicated, data are number of patients, with percentage in parentheses. Low doses: low ruxolitinib (<10 mg BID)/low hydroxyurea (<1000 mg/daily); 
intermediate doses: low ruxolitinib/high hydroxyurea or high ruxolitinib/low hydroxyurea; high doses: ruxolitinib (≥10 mg BID)/high hydroxyurea (≥1000 mg).
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manageable with drug reduction or short discontinuation of com-
bination therapy, is the most frequent side effect of treatment. 
The durability of the responses is variable but can be long‐last-
ing. Nevertheless, given the results of our study, this association 
seems an effective and safe therapy for MF, and in particular for 
hyperproliferative forms of MF, hence, our findings need to be 
validated in a prospective and well‐controlled large trial.
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